Aspira Women's Health Financial Statements (AWH)
|
|
Report date
|
|
|
31.03.2022 |
30.03.2023 |
26.10.2023 |
31.12.2023 |
01.04.2024 |
|
19.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
6.81 |
8.18 |
8.18 |
9.15 |
9.15 |
|
9.26 |
Operating Income, bln rub |
|
|
-32.6 |
-32.8 |
-32.8 |
-18.9 |
-18.9 |
|
-17.2 |
EBITDA, bln rub |
? |
|
-32.3 |
-38.2 |
-30.9 |
-18.9 |
-16.5 |
|
-17.2 |
Net profit, bln rub |
? |
|
-31.7 |
-21.6 |
-21.6 |
-16.7 |
-16.7 |
|
-15.2 |
|
OCF, bln rub |
? |
|
-27.4 |
-32.2 |
-32.2 |
|
-15.9 |
|
-11.1 |
CAPEX, bln rub |
? |
|
0.184 |
0.232 |
0.232 |
|
0.024 |
|
0.037 |
FCF, bln rub |
? |
|
-27.6 |
-32.4 |
-32.4 |
|
-15.9 |
|
-11.1 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
35.7 |
37.1 |
37.1 |
24.1 |
24.1 |
|
22.7 |
Cost of production, bln rub |
|
|
3.75 |
3.87 |
3.87 |
3.89 |
3.89 |
|
3.85 |
R&D, bln rub |
|
|
5.31 |
5.95 |
5.95 |
4.04 |
4.04 |
|
3.72 |
Interest expenses, bln rub |
|
|
0.048 |
0.017 |
0.017 |
0.000 |
0.000 |
|
0.030 |
|
Assets, bln rub |
|
|
41.1 |
17.4 |
17.4 |
6.26 |
6.26 |
|
4.76 |
Net Assets, bln rub |
? |
|
30.2 |
6.73 |
6.73 |
-2.37 |
-2.37 |
|
-2.52 |
Debt, bln rub |
|
|
4.11 |
3.83 |
3.83 |
2.85 |
2.85 |
|
2.14 |
Cash, bln rub |
|
|
37.2 |
13.3 |
13.3 |
2.60 |
2.60 |
|
2.13 |
Net debt, bln rub |
|
|
-33.1 |
-9.48 |
-9.48 |
0.26 |
0.26 |
|
0.01 |
|
Ordinary share price, rub |
|
|
26.6 |
4.95 |
4.95 |
4.08 |
4.08 |
|
4.80 |
Number of ordinary shares, mln |
|
|
7.41 |
0.518 |
0.518 |
9.23 |
9.23 |
|
15.4 |
|
Market cap, bln rub |
|
|
197 |
3 |
3 |
38 |
38 |
|
74 |
EV, bln rub |
? |
|
164 |
-7 |
-7 |
38 |
38 |
|
74 |
Book value, bln rub |
|
|
30 |
7 |
7 |
-2 |
-2 |
|
-3 |
|
EPS, rub |
? |
|
-4.28 |
-41.7 |
-41.7 |
-1.81 |
-1.81 |
|
-0.99 |
FCF/share, rub |
|
|
-3.72 |
-62.6 |
-62.6 |
0.00 |
-1.72 |
|
-0.72 |
BV/share, rub |
|
|
4.07 |
13.0 |
13.0 |
-0.26 |
-0.26 |
|
-0.16 |
|
EBITDA margin, % |
? |
|
-474.1% |
-467.2% |
-377.2% |
-205.9% |
-180.2% |
|
-185.7% |
Net margin, % |
? |
|
-465.5% |
-263.6% |
-263.6% |
-182.3% |
-182.3% |
|
-164.6% |
FCF yield, % |
? |
|
-14.0% |
-1 264% |
-1 264% |
0.00% |
-42.3% |
|
-15.0% |
ROE, % |
? |
|
-105.1% |
-320.5% |
-320.5% |
705.7% |
705.7% |
|
604.6% |
ROA, % |
? |
|
-77.2% |
-124.2% |
-124.2% |
-266.5% |
-266.5% |
|
-320.2% |
|
P/E |
? |
|
-6.21 |
-0.12 |
-0.12 |
-2.26 |
-2.26 |
|
-4.85 |
P/FCF |
|
|
-7.14 |
-0.08 |
-0.08 |
|
-2.37 |
|
-6.64 |
P/S |
? |
|
28.9 |
0.31 |
0.31 |
4.12 |
4.12 |
|
7.99 |
P/BV |
? |
|
6.52 |
0.38 |
0.38 |
-15.9 |
-15.9 |
|
-29.3 |
EV/EBITDA |
? |
|
-5.07 |
0.18 |
0.22 |
-2.01 |
-2.30 |
|
-4.30 |
Debt/EBITDA |
|
|
1.02 |
0.25 |
0.31 |
-0.01 |
-0.02 |
|
0.00 |
|
R&D/CAPEX, % |
|
|
2 888% |
2 566% |
2 566% |
|
16 813% |
|
10 049% |
|
CAPEX/Revenue, % |
|
|
2.70% |
2.83% |
2.83% |
0.00% |
0.26% |
|
0.40% |
|
Aspira Women's Health shareholders |